Enzyme replacement therapy in Fabry disease: Clinical implications

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 5, 2003, Pages 491-495

  Breunig, Frank ^a,b   Knoll, Anita ^a   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Clinical trials; Fabry disease; Genetic disorders; Lysosomal storage disease

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID;

CLINICAL FEATURE; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; GENE TRANSFER; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LYSOSOME STORAGE DISEASE; PRIORITY JOURNAL; REVIEW; X CHROMOSOME LINKED DISORDER;

ALPHA-GALACTOSIDASE; CLINICAL TRIALS; FABRY DISEASE; HUMANS; TREATMENT OUTCOME;

EID: 0042833200     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200309000-00002     Document Type: Review

References (48)

1. th ed. New York: MacGraw Hill; 2001. pp. 3733-3774.
2. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68:711-722.
3. Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000; 97:365-370.
4. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A: replacement therapy in Fabry's disease. N Engl J Med 2001; 345:9-16.
5. Schiffmann R, Kopp JB, Austin HA, 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743-2749.
6. Shabbeer J, Yasuda M, Luca E, Desnick RJ. Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype. Mol Genet Metab 2002; 76:23-30.
7. Altarescu GM, Goldfarb LG, Park KY, et al. Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001; 60:46-51.
8. Kimura K, Sato-Matsumura KC, Nakamura H, et al. A novel A97P amino acid substitution in alpha-galactosidase A leads to a classical Fabry disease with cardiac manifestations. Br J Dermatol 2002; 147:545-548.
9. Ishii S, Nakao S, Minamikawa-Tachino R, et al. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 2002; 70:994-1002.
10. Blaydon D, Hill J, Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat 2001; 18:459.
11. Tse KC, Chan KW, Tin VP, et al. Clinical features and genetic analysis of a Chinese kindred with Fabry's disease. Nephrol Dial Transplant 2003; 18:182-186.
12. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139:1101-1108.
13. Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107:1978-1984.
14. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333:288-293.
15. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407-1411.
16. Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002; 40:1668-1674.
17. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24:715-724.
18. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61:249-255. This was an interesting epidemiological study about Fabry patients on haemodialysis.
19. Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996; 11 (Suppl 7):4-20.
20. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81:122-138. This was an epidemiological study on the natural history of Fabry disease.
21. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104:1506-1512.
22. Altarescu G, Moore DF, Pursley R, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001; 32:1559-1562.
23. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33:525-531.
24. Itoh Y, Esaki T, Cook M, et al. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. J Neurochem 2001; 79:1217-1224.
25. Tedeschi G, Bonavita S, Banerjee TK, et al. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 1999; 52:1663-1667.
26. Miners AH, Holmes A, Sherr L, et al. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res 2002; 11:127-133.
27. Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002; 11:317-327. This is an interesting analysis on issues of quality of life in Fabry patients.
28. Bishop DF, Calhoun DH, Bernstein HS, et al. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A 1986; 83:4859-4863.
29. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62:1933-1946. These authors provide detailed insights into renal pathology and effects of ERT.
30. De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18:33-35. This intersting case report shows stabilization and improvement of organ function with ERT in a severely affected patient.
31. Sakuraba H, Oshima A, Fukuhara Y, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 1990; 47:784-789.
32. Ishii S, Sakuraba H, Suzuki Y. Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 1992; 89:29-32.
33. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324:395-399.
34. Okumiya T, Ishii S, Takenaka T, et al. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun 1995; 214:1219-1224.
35. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999; 5:112-115.
36. Asano N, Ishii S, Kizu H, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 2000; 267:4179-4186.
37. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001; 345:25-32.
38. Jung SC, Han IP, Limaye A, et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A 2001; 98:2676-2681.
39. Takahashi H, Hirai Y, Migita M, et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci U S A 2002; 99:13777-13782. The authors describe a necessary approach for developing new strategies beyond enzyme replacement therapy.
40. Li C, Ziegler RJ, Cherry M, et al. Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease. Mol Ther 2002; 5:745-754.
41. Takenaka T, Murray GJ, Qin G, et al. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A 2000; 97:7515-7520.
42. Estruch EJ, Hart SL, Kinnon C, Winchester BG. Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases. J Gene Med 2001; 3:488-497.
43. Ziegler RJ, Li C, Cherry M, et al. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther 2002; 13:935-945.
44. Ashley GA, Desnick RJ, Gordon RE, Gordon JW. High overexpression of the human alpha-galactosidase A gene driven by its promoter in transgenic mice: implications for the treatment of Fabry disease. J Investig Med 2002; 50:185-192.
45. Breunig F, Weidemann F, Beer M, et al. Fabry disease: diagnosis and treatment. Kidney Int 2003; 63 (Suppl 84):S181-S185.
46. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138:338-346. This presents guidelines for diagnosis and treatment of patients with Fabry disease.
47. Breunig F, Wanner C. Enzyme replacement therapy for Fabry disease: proving the clinical benefit. Nephrol Dial Transplant 2003; 18:7-9.
48. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 2002; 3:954-966. This is an excellent review about lysosomal storage diseases highlighting development of therapeutic strategies in Fabry disease.